The expression profile and clinic significance of the SIX family in non-small cell lung cancer

Abstract

BackgroundThe SIX family homeobox genes have been demonstrated to be involved in the tumor initiation and progression, but their clinicopathological features and prognostic values in non-small cell lung cancer (NSCLC) have not been well defined. We analyzed relevant datasets and performed a systemic review and a meta-analysis to assess the profile of SIX family members in NSCLC and evaluate their importance as biomarkers for diagnosis and prediction of NSCLC.MethodsThis meta-analysis included 17 studies with 2358 patients. Hazard ratio (HR) and 95 % confidence interval (CI) were calculated to represent the prognosis of NSCLC with expression of the SIX family genes. Heterogeneity of the ORs and HRs was assessed and quantified using the Cochrane Q and I 2 test. Begg’s rank correlation method and Egger’s weighted regression method were used to screen for potential publication bias. Bar graphs of representative datasets were plotted to show the correlation between the SIX expression and clinicopathological features of NSCLC. Kaplan-Meier survival curves were used to validate our prognostic analysis by pooled HR.ResultsThe systematic meta-analysis unveiled that the higher expressions of SIX1-5 were associated with the greater possibility of the tumorigenesis. SIX4 and SIX6 were linked to the lymph node metastasis (LNM). SIX2, SIX3, and SIX4 were correlated with higher TNM stages. Furthermore, the elevated expressions of SIX2, SIX4, and SIX6 predicted poor overall survival (OS) in NSCLC (SIX2: HR = 1.14, 95 % CI, 1.00–1.31; SIX4: HR = 1.39, 95 % CI, 1.16–1.66; SIX6: HR = 1.18, 95 % CI, 1.00–1.38) and poor relapse-free survival (RFS) in lung adenocarcinoma (ADC) (SIX2: HR = 1.42, 95 % CI, 1.14–1.77; SIX4: HR = 1.52, 95 % CI, 1.09–2.11; SIX6: HR = 1.25, 95 % CI, 1.01–1.56).ConclusionsOur report demonstrated that the SIX family members play distinct roles in the tumorigenesis of NSCLC and can be potential biomarkers in predicting prognosis of NSCLC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-016-0339-1) contains supplementary material, which is available to authorized users.

SNPs in LncRNA genes are associated with non‐small cell lung cancer in a Chinese population

“…A similar finding was also observed in patients with glioblastoma . A meta‐analysis suggests that SIX3 may play a role in suppressing the progression of lung cancer, especially in its early stage …”

The clinical significance of CXCL5 in non-small cell lung cancer

“…Besides well-known driver genes, many factors contribute to lung cancer pathogenesis and progression. 40 , 41 Various biomarkers have been explored for diagnosis, targeted therapy, or prognosis. 42 – 45 CXCL5 is a member of a proangiogenic subgroup of the CXC-type chemokine family.…”

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer

“…We analyzed relevant Gene Expression Omnibus (GEO) databases for mRNA expression of CXCL1. We obtained these published datasets from ArrayExpress and Oncomine (41). And the included datasets must meet the following criteria: (a) the datasets were about human NSCLC cancer; (b) CXCL1 mRNA expression was measured in these databases; (c) these databases should include clinical characteristics of patients.…”